Literature DB >> 26729196

Immunotherapy of biliary tract cancer.

Yi Chai1.   

Abstract

Biliary tract cancers (BTCs), which encompass intra- and extrahepatic cholangiocarcinomas as well as gallbladder carcinomas, are one of the most aggressive malignancies. Although the development of systemic chemotherapy approaches has made progress, the prognosis of BTC remains poor. Chronic inflammation plays an important role in the carcinogenesis of BTC, highlighting the immune etiology of this disease. Immunotherapy has emerged as a promising new modality of treatment for BTC. Here, we summarize the relevant tumor immunology of BTC and recently completed and ongoing clinical trials of immunotherapy for BTC.

Entities:  

Keywords:  Biliary tract cancer; Cholangiocarcinoma; Immunotherapy

Mesh:

Substances:

Year:  2016        PMID: 26729196     DOI: 10.1007/s13277-015-4743-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  48 in total

1.  Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma.

Authors:  Koichi Shimizu; Yoshihito Kotera; Atsushi Aruga; Nobuhiro Takeshita; Ken Takasaki; Masakazu Yamamoto
Journal:  J Hepatobiliary Pancreat Sci       Date:  2012-03       Impact factor: 7.027

2.  The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF.

Authors:  Kai-Uwe Belge; Farshid Dayyani; Alexia Horelt; Maciej Siedlar; Marion Frankenberger; Bernhard Frankenberger; Terje Espevik; Löms Ziegler-Heitbrock
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

Review 3.  Outcomes in biliary malignancy.

Authors:  Bas Groot Koerkamp; Yuman Fong
Journal:  J Surg Oncol       Date:  2014-10       Impact factor: 3.454

4.  Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma.

Authors:  M Higashi; S Yonezawa; J J Ho; S Tanaka; T Irimura; Y S Kim; E Sato
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

5.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

6.  Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma.

Authors:  Naoki Matsumura; Masakazu Yamamoto; Atsushi Aruga; Ken Takasaki; Masayuki Nakano
Journal:  Cancer       Date:  2002-03-15       Impact factor: 6.860

7.  Immunization with aspartate-β-hydroxylase-loaded dendritic cells produces antitumor effects in a rat model of intrahepatic cholangiocarcinoma.

Authors:  Takehiro Noda; Masafumi Shimoda; Vivian Ortiz; Alphonse E Sirica; Jack R Wands
Journal:  Hepatology       Date:  2012-01       Impact factor: 17.425

8.  Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.

Authors:  Eric Tran; Simon Turcotte; Alena Gros; Paul F Robbins; Yong-Chen Lu; Mark E Dudley; John R Wunderlich; Robert P Somerville; Katherine Hogan; Christian S Hinrichs; Maria R Parkhurst; James C Yang; Steven A Rosenberg
Journal:  Science       Date:  2014-05-09       Impact factor: 47.728

9.  Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.

Authors:  Makiko Taniai; Annette Grambihler; Hajime Higuchi; Nate Werneburg; Steve F Bronk; Daniel J Farrugia; Scott H Kaufmann; Gregory J Gores
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

10.  Simultaneous detection of epidermal growth factor receptor (EGF-R), epidermal growth factor (EGF) and ras p21 in cholangiocarcinoma by an immunocytochemical method.

Authors:  A Nonomura; G Ohta; Y Nakanuma; R Izumi; Y Mizukami; F Matsubara; M Hayashi; K Watanabe; N Takayanagi
Journal:  Liver       Date:  1988-06
View more
  6 in total

1.  Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma.

Authors:  Thanpisit Lomphithak; Perawatt Akara-Amornthum; Keigo Murakami; Masatoshi Hashimoto; Hajime Usubuchi; Erina Iwabuchi; Michiaki Unno; Zhenyu Cai; Hironobu Sasano; Siriporn Jitkaew
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

2.  High CD8+ and absence of Foxp3+ T lymphocytes infiltration in gallbladder tumors correlate with prolonged patients survival.

Authors:  Paula Fluxá; Daniel Rojas-Sepúlveda; María Alejandra Gleisner; Andrés Tittarelli; Pablo Villegas; Loreto Tapia; María Teresa Rivera; Mercedes Natalia López; Felipe Catán; Mario Uribe; Flavio Salazar-Onfray
Journal:  BMC Cancer       Date:  2018-03-02       Impact factor: 4.430

3.  Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma.

Authors:  Kamonlapat Supimon; Thanich Sangsuwannukul; Jatuporn Sujjitjoon; Nattaporn Phanthaphol; Thaweesak Chieochansin; Naravat Poungvarin; Sopit Wongkham; Mutita Junking; Pa-Thai Yenchitsomanus
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

4.  Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status.

Authors:  Kota Sahara; S Ayesha Farooq; Diamantis I Tsilimigras; Katiuscha Merath; Anghela Z Paredes; Lu Wu; Rittal Mehta; J Madison Hyer; Itaru Endo; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2020-02       Impact factor: 7.293

Review 5.  Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer.

Authors:  Daniel Rojas-Sepúlveda; Andrés Tittarelli; María Alejandra Gleisner; Ignacio Ávalos; Cristián Pereda; Iván Gallegos; Fermín Eduardo González; Mercedes Natalia López; Jean Michel Butte; Juan Carlos Roa; Paula Fluxá; Flavio Salazar-Onfray
Journal:  Cancer Immunol Immunother       Date:  2018-03-29       Impact factor: 6.968

6.  Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology.

Authors:  Hyerim Ha; Ju-Hee Bang; Ah-Rong Nam; Ji-Eun Park; Mei Hua Jin; Yung-Jue Bang; Do-Youn Oh
Journal:  Cancer Res Treat       Date:  2018-10-05       Impact factor: 4.679

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.